Muhammad Awidi: Metabolic health and its impact on ICIs
Muhammad Awidi, Hematology and Oncology Fellow at Roswell Park Cancer Center, shared a post on LinkedIn:
“The obesity paradox, with its intriguing link to improved Immune Checkpoint Inhibitor (ICI) response, has been well-documented. Building on this, our latest paper dives deeper into metabolic health and its impact on ICIs.
Key Insights:
Baseline glucose levels and dyslipidemia were independently associated with shorter overall survival (OS) in patients with NSCLC treated with ICIs.
These associations held true regardless of T2DM status or use of glucose-/lipid-lowering medications, even after adjusting for confounders like glucocorticoid use, BMI, performance status, and immune-related adverse events.
Why Does This Matter?
These findings point to the crucial role of T-cell metabolic pathways—specifically glycolysis and lipid metabolism—in potentially driving T-cell exhaustion and limiting immune response efficacy.
Future Directions:
Understanding and targeting these metabolic pathways could open new doors for enhancing ICI responses, paving the way for truly personalized cancer therapy.
Read the full paper.”
Authors: Soravis Osataphan, Muhammad Awidi, Yu Jen Jan, Krishna Gunturu, Shriram Sundararaman, Hollis Viray, Edward Frankenberger, Melissa Mariano, Lauren O’Loughlin, Andrew Piper-Vallillo, Katherine Stafford, Aleksandra Kolnick, Hind Ghazalah, Kartik Sehgal, Mary-Elizabeth Patti, Daniel Costa, Prudence Lam, Deepa Rangachari.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023